Efficacy of galantamine hydrobromide in treatment of mild cognitive impairment after stroke
Wu Ya-ping
Sun Wen-qiang
Ji Hai-xia
Wang Hong-liang
Abstract：Objective To explore the efficacy of galantamine hydrobromide in treatment of patients with mild cognitive im-pairment after stroke and its effect on serum levels of neuron specific enolase(NSE)and homocysteine(Hcy).Methods A total of 120 patients with mild cognitive impairment after stroke admitted to Nantong Sixth People's Hospital from February 2022 to August 2023 were divided into two groups using a random number table method.The 60 patients in the control group received standardized stroke treatment while the other 60 patients in the observation group were treated with galantamine hydrobromide tablets based on the regimen in the control group for a continuous period of 3 months.The serum NSE,Hcy levels,cognitive function scores be-fore and after treatment were compared between the two groups.The clinical efficacy and incidence of adverse reactions were also evaluated.Results After treatment,the serum levels of NSE and Hcy in the control group and observation group were(20.86±3.03)pg·mL-1 vs(16.24±2.76)pg·mL-1,(19.78±3.16)μmol·L-1 vs(16.35±3.09)μmol·L-1,respectively,which were lower than before treatment((27.04±3.68)pg·mL-1 vs(27.61±3.54)pg·mL-1,(22.88±3.84)μmol·L-1 vs(23.14±3.62)μmol·L-1),and the serum levels of NSE and Hcy in the observation group were lower than those in the control(t=8.731,6.011,both P<0.05).The scores of Montreal cognitive assessment scale(MOCA)and mini mental state examination(MMSE)in the two groups were(21.28±2.16)points vs(24.35±2.55)points,(21.86±2.53)points vs(25.61±2.28)points,which were higher than those before treatment((19.92±2.64)points vs(19.32±2.06)points,(17.06±1.48)points vs(17.28±1.59)points),respectively.Meanwhile,the MMSE and MOCA scores in the obser-vation group were higher than those in the control(t=8.529,7.19,both P<0.05).The total effective rate of the observation group was 96.67%(58/60),which was higher than the control's 81.67%(49/60)(χ2=6.988,P=0.008).The incidence of adverse reactions in the observation group was 15.00%(9/60),higher than that in the control(10.00%(6/60)),showing no statistically significant difference(χ2=0.686,P=0.408).Conclusion Galantamine hydrobromide has good efficacy and safety in treating patients with mild cognitive impairment after stroke by improving their cognitive function and reducing their serum NSE and Hcy levels.
Keywords：Galantamine hydrobromideStrokeCognitive dysfunctionHomocysteineMental state
Publication Date：2025-02-24
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 5-8,17 )